Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 865 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Relapsed, Refractory Multiple Myeloma Clear all

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Pomalidomide, Dexamethasone, Nivolumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 22
States / cities: Mobile, Alabama • Santa Barbara, California • Denver, Colorado + 17 more

Conditions: Multiple Myeloma
Interventions: Elranatamab, Standard of care; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Weeks and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Bortezomib, Metformin Hydrochloride, Nelfinavir Mesylate; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Talquetamab, Ciltacabtagene Autoleucel; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Multiple Myeloma
Interventions: CC-95266, Fludarabine, Cyclophosphamide, Bendamustine; Drug
Lead sponsor: Juno Therapeutics, a Subsidiary of Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 10
States / cities: Birmingham, Alabama • Duarte, California • San Francisco, California + 7 more

Conditions: Refractory Multiple Myeloma
Interventions: carfilzomib, dexamethasone, laboratory biomarker analysis; Drug · Other
Lead sponsor: Attaya Suvannasankha; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Advanced Cancer, Various, NOS
Interventions: BMS-833923, Lenalidomide, Dexamethasone, Bortezomib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 8
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 5 more

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: donor lymphocytes; Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: Up to 76 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)
Interventions: Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapy: Fludarabine, Lisocabtagene Maraleucel, Axicabtagene Ciloleucel, Ciltacabtagene Autoleucel, Low-Dose Total Body Irradiation; Drug · Other · Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: New York, New York

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Carfilzomib, Dexamethasone, Telaglenastat Hydrochloride; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 5
States / cities: New Haven, Connecticut • Tampa, Florida • Rochester, Minnesota + 2 more

Conditions: Multiple Myeloma
Interventions: POM, Steroids, PLD, CFZ, BTZ, CLA, CY; Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 12
States / cities: Encinitas, California • Fountain Valley, California • Palm Springs, California + 9 more

Conditions: Cancer
Interventions: graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation; Biological · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: Up to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Myeloproliferative Disorders, Cognitive/Functional Effects, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Not listed
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2030
U.S. locations: 7
States / cities: Boone, North Carolina • Chapel Hill, North Carolina • Greenville, North Carolina + 4 more

Conditions: Multiple Myeloma
Interventions: velcade, Pralatrexate; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Multiple Myeloma
Interventions: DARATUMUMAB, DURVALUMAB; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 12
States / cities: Duarte, California • Southington, Connecticut • Fort Wayne, Indiana + 8 more

Conditions: Relapsed and Refractory Multiple Myeloma
Interventions: LGH447, BYL719; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Houston, Texas • Seattle, Washington • Madison, Wisconsin

Conditions: Multiple Myeloma
Interventions: Ibrutinib, Pomalidomide, Dexamethasone, Placebo; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 5
States / cities: Duarte, California • Boston, Massachusetts • Cleveland, Ohio + 2 more

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide, etoposide; Biological · Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: Up to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: Venetoclax, Dexamethasone; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 21
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • New Haven, Connecticut + 18 more

Conditions: Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma Refractory, Multiple Myeloma in Relapse
Interventions: EZM0414; Drug
Lead sponsor: Epizyme, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 8
States / cities: Duarte, California • East Brunswick, New Jersey • New York, New York + 3 more

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: CB-011; Biological
Lead sponsor: Caribou Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 16
States / cities: Birmingham, Alabama • Aurora, Colorado • Miami, Florida + 12 more

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: doxorubicin hydrochloride, motexafin gadolinium; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Madison, Wisconsin

Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Interventions: Cabozantinib; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Omaha, Nebraska • Houston, Texas

Conditions: Multiple Myeloma
Interventions: Group A: Carfilzomib & Non-IMiD Regimen, Group B: Carfilzomib & IMiD containing regimen.; Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 9
States / cities: Encinitas, California • Salinas, California • Santa Maria, California + 6 more

Search by objective public record fields.

A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy

Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Registry of Older Patients With Cancer

Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM

A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma

Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments